BioLife Solutions, Inc. (NASDAQ:BLFS) Director Andrew G. Hinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 15th. The stock was sold at an average price of $33.80, for a total value of $84,500.00. Following the completion of the sale, the director now owns 12,473 shares of the company’s stock, valued at approximately $421,587.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
BLFS stock traded down $1.46 during midday trading on Monday, reaching $32.71. 195,881 shares of the company’s stock traded hands, compared to its average volume of 308,300. The company has a 50-day simple moving average of $36.64 and a two-hundred day simple moving average of $36.79. BioLife Solutions, Inc. has a 1-year low of $10.00 and a 1-year high of $47.97. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -44.81, a PEG ratio of 50.41 and a beta of 1.55.
BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Sunday, March 21st. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.04). BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%. The business had revenue of $14.73 million for the quarter, compared to analyst estimates of $13.43 million. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post 0.01 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. Tower House Partners LLP acquired a new stake in BioLife Solutions during the 4th quarter valued at $18,872,000. UBS Asset Management Americas Inc. acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $1,041,000. EMC Capital Management acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $1,283,000. Principal Financial Group Inc. acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $264,000. Finally, JPMorgan Chase & Co. increased its stake in shares of BioLife Solutions by 86.6% in the 4th quarter. JPMorgan Chase & Co. now owns 222,521 shares of the medical equipment provider’s stock valued at $8,876,000 after buying an additional 103,276 shares during the period. 67.66% of the stock is owned by hedge funds and other institutional investors.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Article: Do equity income investments outperform growth and income investments?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.